These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16776018)

  • 1. How much is more life worth?
    Brock DW
    Hastings Cent Rep; 2006; 36(3):17-9. PubMed ID: 16776018
    [No Abstract]   [Full Text] [Related]  

  • 2. The costs of caring: Who pays? Who profits? Who panders?
    Fleck LM
    Hastings Cent Rep; 2006; 36(3):13-7. PubMed ID: 16776017
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges and opportunities for use of cost-effectiveness analysis.
    Yabroff KR; Schrag D
    J Natl Cancer Inst; 2009 Sep; 101(17):1161-3. PubMed ID: 19666852
    [No Abstract]   [Full Text] [Related]  

  • 4. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
    Fojo T; Grady C
    J Natl Cancer Inst; 2009 Aug; 101(15):1044-8. PubMed ID: 19564563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
    Cohen J; Looney W
    J Natl Cancer Inst; 2010 Aug; 102(15):1207; author reply 1207-10. PubMed ID: 20651322
    [No Abstract]   [Full Text] [Related]  

  • 7. Costly cancer drugs trigger proposals to modify clinical trial design.
    Schmidt C
    J Natl Cancer Inst; 2009 Dec; 101(24):1662-4. PubMed ID: 19933943
    [No Abstract]   [Full Text] [Related]  

  • 8. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
    Rinaldi F; George E; Adler AI
    Lancet Oncol; 2012 Mar; 13(3):233-4. PubMed ID: 22489288
    [No Abstract]   [Full Text] [Related]  

  • 9. Makers of anticancer drugs are "profiteering," say 100 specialists from around the world.
    Laurance J
    BMJ; 2013 Apr; 346():f2810. PubMed ID: 23633224
    [No Abstract]   [Full Text] [Related]  

  • 10. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 11. Promising drug is victim of bad business.
    Dove A
    Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
    [No Abstract]   [Full Text] [Related]  

  • 12. The art of mismanagement.
    Nat Biotechnol; 2006 Nov; 24(11):1300. PubMed ID: 17093455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer drugs offer hope, but at huge expense.
    Berenson A
    N Y Times Web; 2005 Jul; ():A1, C3. PubMed ID: 16075470
    [No Abstract]   [Full Text] [Related]  

  • 14. Pricing increases for cancer drugs sparks investigation.
    Venkatesan P
    Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
    [No Abstract]   [Full Text] [Related]  

  • 15. Trastuzumab for early breast cancer: evolution or revolution?
    Littlejohns P
    Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378
    [No Abstract]   [Full Text] [Related]  

  • 16. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ranibizumab saga of drug profiteering.
    Lee AC; Radford J
    BMJ; 2008 Sep; 337():a1532. PubMed ID: 18768564
    [No Abstract]   [Full Text] [Related]  

  • 19. Watchdog set to reject four drugs for kidney cancer on the NHS.
    O'Dowd A
    BMJ; 2008 Aug; 337():a1262. PubMed ID: 18703648
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
    BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.